Lu Chun-Mei, Kwan Johnson, Weier Jingly F, Baumgartner Adolf, Wang Mei, Escudero Tomas, Munné Santiago, Weier Heinz-Ulrich G
Department of Chemical and Materials Engineering, National Chin-Yi University of Technology, Taiping City, Taichung 411, Taiwan.
Folia Histochem Cytobiol. 2009 Jan;47(3):367-75. doi: 10.2478/v10042-009-0067-2.
Structural chromosome aberrations and associated segmental or chromosomal aneusomies are major causes of reproductive failure in humans. Despite the fact that carriers of reciprocal balanced translocation often have no other clinical symptoms or disease, impaired chromosome homologue pairing in meiosis and karyokinesis errors lead to over-representation of translocations carriers in the infertile population and in recurrent pregnancy loss patients. At present, clinicians have no means to select healthy germ cells or balanced zygotes in vivo, but in vitro fertilization (IVF) followed by preimplantation genetic diagnosis (PGD) offers translocation carriers a chance to select balanced or normal embryos for transfer. Although a combination of telomeric and centromeric probes can differentiate embryos that are unbalanced from normal or unbalanced ones, a seemingly random position of breakpoints in these IVF-patients poses a serious obstacle to differentiating between normal and balanced embryos, which for most translocation couples, is desirable. Using a carrier with reciprocal translocation t(4;13) as an example, we describe our state-of-the-art approach to the preparation of patient-specific DNA probes that span or 'extent' the breakpoints. With the techniques and resources described here, most breakpoints can be accurately mapped in a matter of days using carrier lymphocytes, and a few extra days are allowed for PGD-probe optimization. The optimized probes will then be suitable for interphase cell analysis, a prerequisite for PGD since blastomeres are biopsied from normally growing day 3--embryos regardless of their position in the mitotic cell cycle. Furthermore, routine application of these rapid methods should make PGD even more affordable for translocation carriers enrolled in IVF programs.
结构性染色体畸变以及相关的节段性或染色体非整倍体是人类生殖失败的主要原因。尽管相互平衡易位携带者通常没有其他临床症状或疾病,但减数分裂中染色体同源配对受损和核分裂错误导致易位携带者在不育人群和复发性流产患者中占比过高。目前,临床医生无法在体内选择健康的生殖细胞或平衡的受精卵,但体外受精(IVF)后进行植入前基因诊断(PGD)为易位携带者提供了选择平衡或正常胚胎进行移植的机会。尽管端粒和着丝粒探针的组合可以区分不平衡胚胎与正常或不平衡胚胎,但这些IVF患者中断点位置看似随机,这对区分正常和平衡胚胎构成了严重障碍,而对于大多数易位夫妇来说,这是他们所期望的。以携带相互易位t(4;13)的携带者为例,我们描述了我们制备跨越或“延伸”断点的患者特异性DNA探针的先进方法。利用本文所述的技术和资源,使用携带者淋巴细胞,大多数断点可以在几天内准确绘制出来,还需要额外几天进行PGD探针优化。优化后的探针将适用于间期细胞分析,这是PGD的前提条件,因为无论卵裂球在有丝分裂细胞周期中的位置如何,都从正常发育的第3天胚胎中进行活检。此外,这些快速方法的常规应用应该会使PGD对于参加IVF计划的易位携带者来说更加经济实惠。